Advertisement
Canada markets close in 6 hours 5 minutes
  • S&P/TSX

    21,946.63
    +61.25 (+0.28%)
     
  • S&P 500

    5,097.96
    +49.54 (+0.98%)
     
  • DOW

    38,247.89
    +162.09 (+0.43%)
     
  • CAD/USD

    0.7319
    -0.0005 (-0.06%)
     
  • CRUDE OIL

    84.05
    +0.48 (+0.57%)
     
  • Bitcoin CAD

    87,945.16
    +1,477.37 (+1.71%)
     
  • CMC Crypto 200

    1,383.71
    -12.82 (-0.96%)
     
  • GOLD FUTURES

    2,349.30
    +6.80 (+0.29%)
     
  • RUSSELL 2000

    1,988.70
    +7.59 (+0.38%)
     
  • 10-Yr Bond

    4.6550
    -0.0510 (-1.08%)
     
  • NASDAQ

    15,890.31
    +278.55 (+1.78%)
     
  • VOLATILITY

    15.44
    +0.07 (+0.46%)
     
  • FTSE

    8,133.05
    +54.19 (+0.67%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6830
    +0.0009 (+0.13%)
     

How Is Olumiant Positioned after 3Q17?

In 3Q17, Eli Lilly's (LLY) Olumiant (baricitinib) reported revenues of $16.2 million compared to $4.8 million and $1.9 million in 2Q17 and 1Q17, respectively.